Skip to main content


Buy Article:

$63.00 plus tax (Refund Policy)


In our review entitled “Radioligand Development for PET Imaging of -Amyloid (Aβ) ” Current Status” by Cai, et al. in Current Medicinal Chemistry, 2007, 14 , 19-52.

Please note brain uptake values at 2, 30, and 60 min in Table 23 are not uniformly in %SUV [(%ID/g) x g (body weight)] as implied. For example, the data shown are [(%ID/g) x kg (body weight)] for PIB in mouse and %ID/g for IMPY also in mouse. Because the average mouse weighs about 30 g (0.03 kg), the value for IMPY would need to be corrected by a factor of about 0.03 to be directly comparable with that of PIB. A compound with a brain uptake of 0.21 %ID/g at 2 min would not be the same as PIB. In fact, that compound would be about 30-fold inferior to PIB with regard to brain uptake and would likely fail as an in vivo imaging agent.

The numbers are taken directly from the original references. Due to lack of animal body weight data and the different species from which data had been obtained, strictly comparable SUV values could not be calculated. However, these differences were mistakenly not noted in the Table. Interested readers should consult the original references for details. The ratios of radioactivity between 2 and 30 min, or 2 and 60 min, as listed in the Table remain correct. We apologize for this error and the inconvenience to the reader.

Document Type: Research Article


Affiliations: Molecular Imaging Branch National Institute of Mental Health National Institutes of Health Bethesda, MD 20892 USA.

Publication date: 2007-06-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more